Tenecteplase versus standard care for minor ischaemic stroke according to the baseline occlusion status in TEMPO-2 trial
Silja Räty, Daniel Strbian, Nishita Singh, Shabnam Vatanpour, Liisa Tomppo, Aravind Ganesh, Bruce C V Campbell, Mark W Parsons, Michael D Hill, Shelagh B Coutts · 2026
Read Tenecteplase versus standard care for minor ischaemic stroke according to the baseline occlusion status in TEMPO-2 trial by Silja Räty, Daniel Strbian, Nishita Singh, Shabnam Vatanpour, Liisa Tomppo, Aravind Ganesh, Bruce C V Campbell, Mark W Parsons, Michael D Hill, Shelagh B Coutts (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13573578.txt.
Description
Räty and co-authors revisit a trial of a clot-busting drug for the mildest strokes. The TEMPO-2 trial gave tenecteplase or standard care to patients whose stroke scores were low but whose scans showed a blocked vessel or a starved patch of brain. Overall the drug did not help, so this analysis asks whether the answer changes with how blocked the vessel was at the start.
Patients split into complete blockage, near blockage, and no visible blockage. In none of the three groups does the drug beat standard care on returning to prior function at ninety days. The authors conclude that for minor stroke, the vessel's starting state does not rescue the case for this treatment.
Catalog record
| CREATOR | Silja Räty, Daniel Strbian, Nishita Singh, Shabnam Vatanpour, Liisa Tomppo, Aravind Ganesh, Bruce C V Campbell, Mark W Parsons, Michael D Hill, Shelagh B Coutts |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |